吉非替尼对于化疗失败的晚期肺腺癌的疗效及生存观察

目的：观察吉非替尼在化疗失败的晚期肺腺癌中的疗效、生存时间及影响因素。方法：收集２１例初始化疗失败的转移性肺腺癌，应用吉非替尼２５０ｍｇ口服，每日１次，直至出现有客观证据的病情进展，或出现不可耐受的不良反应。用Ｋａｐｌａｎ-Ｍｅｉｅｒ法拟定生存曲线，采用Ｌｏｇｒａｎｋ检验分析生存因素。结果：２１例患者中ＣＲ３例（１４.３％），ＰＲ例８（３８.１％），ＳＤ３例（１４.３％），ＰＤ７例（３３.３％）。客观缓解率为５２.４％，疾病控制率为６６.７％。中位无进展生存时间（ＰＦＳ）为６个月，中位生存时间（ＯＳ）为８个月。１年生存率为３３.３％（７／２１），２年生存率为９５％（２／２１）。好的ＰＳ评分与生存期延长显著相关（Ｐ＜０.０１）。结论：吉非替尼对既往化疗失败的晚期肺腺癌疗效好，能有效改善生存时间，体力状态评分与吉非替尼治疗的生存时间相关。

Survival and efficacy of gefitinib in previously treated patients with advanced lung adenocarcinoma

Objective：To observe the survival and efficacy of gefitinib in previously treated patients with late stage lung adenocarcinoma.Methods：A total of 21 previously treated patients with advanced lung adenocarcinoma were enrolled in the study.Gefitinib was orally administered 250mg once daily until disease progression or the occurrence of intolerable toxicity.Survival curves were made by Kaplan-Meier method and survival correlation factors were analyzed by log rank test.Results：In 21 patients,there were 3 cases with complete regression（14.3%）,8 cases with partial response（38.1%）,3 cases with stable disease（14.3%） and 7 cases with progression of disease（33.3%）.The objective response rate was 52.4% and the disease control rate was 66.7%.The median progression-free survival time was 6 months and the median overall survival time was 8 months.1-,2-year survival rate was 33.3%（7/21） and 9.5%（2/21）.Good performance status was significantly associated with long survival（P〈0.01）.Conclusion：Gefitinib is an effective target drug for previously treated patients with late stage lung adenocarcinoma and could improve their survival time.Performance status is a significant survival correlation factor.